TearScience
-
New CFO for TearScience as the device firm weighs acquisition, IPO plans
Dry eye treatment company TearScience, which is considering plans for an initial public stock offering, […]
-
If TearScience does a healthcare IPO, it may be in China
TearScience, the dry eye treatment company fresh off a 510(k) clearance, is starting to explore […]
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
How TearScience’s dry eye treatment sparked a new FDA 510(k) strategy
The dry eye treatment developed by TearScience received 510(k) clearance last week, about seven months […]
-
Dry eye treatment from TearScience gets FDA 510(k) clearance
Medical device company TearScience has received 510(k) clearance on the latest version of its evaporative […]
-
TearScience lands $15M to bring novel dry eye treatment to market
Medical device company TearScience has secured $15 million in debt financing that the company will […]
-
Allergan veteran to lead TearScience European business
Medical device company TearScience has hired a former Allergan (NYSE:AGN) executive to spearhead European commercialization […]
-
Medical device dry-eye treatment LipiFlow wins FDA approval
A medical device dry-eye treatment that wants to replace eye drops has received U.S. Food […]